Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
MaxCyte Inc on Wednesday said it had signed a strategic platform licence with Lion TCR to promote the latter’s T cell receptor-T cell pipeline.
MaxCyte is a Maryland, US-based provider of cell engineering platform technologies developing ‘next-generation cell therapeutics’.
The company will partner with the Singapore-based biotechnology company, which advances TCR-T cell therapies for tumours and life-threatening viral infections.
MaxCyte claims that the joint venture will help to promote Lion’s TCR-T cell therapies, while also ‘enhanc[ing] MaxCyte’s presence in Asia’. The partnership will also offer the possibility of expansion into American and European markets.
Under the terms of the deal, Lion will obtain worldwide non-exclusive rights to use MaxCyte’s unique electroporation technology and its trademarked ExPERT research instrument portfolio. In exchange, MaxCyte will receive annual licence fees and programme-related revenue.
MaxCyte Chief Executive Officer Maher Masoud said: ‘Through this important partnership, we will be able to help provide the opportunity for patients in Asia (and ultimately patients worldwide) to benefit from these innovative MRNA-based TCR-T cell treatments and continue supporting the development of new therapies for patients with solid tumours’.
Shares in MaxCyte were up 5.9% at 397.00 pence each in London on Wednesday afternoon.
Copyright 2023 Alliance News Ltd. All Rights Reserved.